Dr Reddy’s Q2 Preview: High base to play spoilsport, outlook for US, Russia in focus
Dr Reddy’s topline will continue to be aided by sales contributions from the cancer drug Revlimid’s generic. While the overall revenue growth in North America, which makes for 50% of the total sales, is expected to be constrained by price erosion, India is likely to have done well.
